EXTENTORCH
Regimen
- Experimental
- toripalimab + etoposide + platinum (EP)
- Control
- placebo + etoposide + platinum (EP)
Population
Treatment-naive extensive-stage small-cell lung cancer (Chinese population)
Key finding
mOS 14.6 vs 13.3 mo (HR 0.80, 95% CI 0.65-0.98, P=0.03); PFS HR 0.67 (95% CI 0.54-0.82, P<0.001)
Source: PMID 39541202
Timeline
Guideline citations
- CSCO SCLC 2025 (p.36)⚠️ OCR source